دانلود کتاب اطفال در حال بررسی

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in: • Neonates and infants born during or entering their fi rst RSV season. • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients. • Hypersensitivity Reactions Including Anaphylaxis: Serious hypersensitivity reactions have been reported following Beyfortus administration. These reactions included urticaria, dyspnea, cyanosis, and/or hypotonia. Anaphylaxis has been observed with human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs and symptoms of anaphylaxis or other clinically signifi cant hypersensitivity reactions occur, initiate appropriate treatment.